Cabozantinib: role and indications of a multi-target tyrosine kinase inhibitor

Cabozantinib (Cabozantinib) is an oral multi-target tyrosine kinase inhibitor (TKI). Its main ingredient is cabozantinib maleate. The drug can target a variety of kinases, including MET, VEGFR, AXL, RET, etc. These signaling pathways play a key role in tumor growth, angiogenesis, invasion and drug resistance. Cabozantinib inhibits the growth and metastasis of cancer cells by inhibiting the activity of these kinases, blocking tumor cell proliferation and reducing angiogenesis in the tumor microenvironment.

In terms of indications, cabozantinib has been approved by the FDA for the treatment of a variety of solid tumors, including advanced renal cell carcinoma (RCC) and differentiated thyroid cancer (DTC), hepatocellular carcinoma (HCC), and medullary thyroid cancer (MTC). Among them, in the treatment of renal cell carcinoma, cabozantinib can be used as a single agent or in combination with an immune checkpoint inhibitor (such as nivolumab) for first-line or second-line treatment; for hepatocellular carcinoma, cabozantinib is suitable for patients who have failed sorafenib treatment. In addition, the drug is also used to treat locally advanced or metastatic medullary thyroid cancer, especially patients with RET mutations.

In terms of therapeutic mechanism, the multi-target inhibitory effect of cabozantinib can not only directly inhibit the proliferation of tumor cells, but also reduce tumor angiogenesis by inhibiting VEGFR, making the tumor microenvironment unfavorable for the survival of cancer cells. At the same time, cabozantinib can overcome tumor resistance to VEGFR inhibitors and improve anti-tumor efficacy by targeting MET and AXL. This unique mechanism of action enables it to exhibit significant anti-cancer activity in multiple tumor types and show good therapeutic effects in multiple clinical studies.

In summary, cabozantinib is a highly effective multi-target tyrosine kinase inhibitor suitable for the treatment of a variety of advanced solid tumors. Its wide range of target effects can not only directly inhibit tumor cell proliferation, but also improve the tumor microenvironment, thus enhancing the anti-tumor effect. Although cabozantinib may cause side effects such as hypertension, diarrhea, and hand-foot syndrome, the patient's tolerance can be improved through reasonable dose adjustment and supportive treatment, and the treatment effect can be further optimized.

Reference:https://en.wikipedia.org/wiki/Cabozantinib